HighTower Advisors’s Prime Medicine PRME Stock Holding History
Bought
Maintained
Sold
Other funds holding PRME
HighTower Advisors's PRME Position: Q3 2026 in Review
HighTower Advisors reduced its Prime Medicine (PRME) stake by 88% in Q3 2026, selling an estimated $997K and leaving 40,351 shares worth $123K. The position accounts for ﹤0.01% of the portfolio, ranked #3653.
HighTower Advisors first reported a position in PRME in Q2 2023 and has held it in 14 quarters since. The position peaked at $1.85M in Q3 2025. 134 funds tracked by Wall St. Rank hold PRME as of Q3 2026.
- HighTower Advisors held 40,351 shares of Prime Medicine worth $123K as of Q3 2026.
- HighTower Advisors sold 300,014 Prime Medicine shares in Q3 2026, an estimated $997K.
- Prime Medicine made up ﹤0.01% of HighTower Advisors's portfolio in Q3 2026, its #3653 holding.
- HighTower Advisors first reported a position in Prime Medicine in Q2 2023 and has held it in 14 quarters since.
- HighTower Advisors's Prime Medicine position peaked at $1.85M in Q3 2025.
- 134 funds tracked by Wall St. Rank held Prime Medicine as of Q3 2026.
Based on HighTower Advisors's 13F filing for Q3 2026, filed 10 Nov 2026.